Subscribe
Subscribe
君实生物
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies. It has a wide range of technologies, including molecular antibody screening, construction of high-yield stable CHO cell lines and therapeutic antibody analysis and detection. As of the date of this prospectus, a total of 6 drugs have been formally established and are in the research and development stage, and the two drugs which are currently in rapid progress are recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) and recombinant humanized anti-PCSK9 monoclonal antibody injection (JS002).
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies. It has a wide range of technologies, including molecular antibody screening, construction of high-yield stable CHO cell lines and therapeutic antibody analysis and detection. As of the date of this prospectus, a total of 6 drugs have been formally established and are in the research and development stage, and the two drugs which are currently in rapid progress are recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) and recombinant humanized anti-PCSK9 monoclonal antibody injection (JS002).
Neusoft Medical Launches Ten New Products and Online Shopping Mall
Realcan's Digital Healthcare Branch Launches New Service Platform
3D Medicines Diagnosis Raises CNY 1.5 Bn after Being Spun-off
Beijing Immunochina Pharmaceutical Closes Series C+ at CNY 100 Mn
Varian Medical Strikes CIIE with Digital Solution for Oncology
GeneMind Biotech Closes Series B of CNY 140 Mn
Chinese Biotech Zai Laboratory Lands on HKEX after 3 Years' Listing on Nasdaq
AI-Based Drug Research Platform XtalPi Closes Series C at USD 318.8 Mn
Broncus Biotech Closes Series C of Multi-Tens Millions US Dollars
China's NMPA Reduces Paperwork for Inland Producers to Make Exotic Medical Devices
Top-Tier CDMO Heyuan China Closes Series C at over CNY 300 Mn
Tongshu Gene Closes Series B of Multi-Hundreds Millions
Medical Cosmetic Manufacture IMEIK Goes Public, Raising CNY 3.57 Bn
JD Health’s New Move on Hong Kong IPO
Biotech IMAB’s In-Process New Drug Enters Clinical Trials
3D Printing Precision Medicine Industry Park Lands in Hunan
Antibody Developer Biocytogen Closes Series D+ at CNY 790 Mn
Edge Medical Robotics Closes Pre Series B at Over CNY 100 Mn
Nasdaq-listed Biotech ZLAB Passes the Hearing for Hong Kong IPO
Genor Biopharma Passes the Hearing for Hong Kong IPO
EqualOcean is an international information service provider and investment research firm that aims to become a global platform for industrial innovation.
We strive to make technology inclusive, accessible and transparent.
Join over 70,000 of your peers
Beijing
9 Xiaguangli, 10F Block A CEC Development Mansion, Chaoyang Dc, Beijing 100125, China
Shanghai
A002, 5F, Ai Tower, 701 Yunjin Road, Xuhui Dc, Shanghai 200232, China
New York
800 Third Ave, 28F, New York, NY 10022, USA
Cooperation strategy
Products & prices
Customers & evaluation
